Lilium Announces Pricing of $114 Million Financing
MUNICH, Germany, May 24, 2024 (GLOBE NEWSWIRE) — Lilium N.V. (NASDAQ: LILM) (“Lilium” or the “Company”), developer of the first […]
Safe & Green Holdings Receives Crucial International Code Council (ICC), Recertification for Use of Shipping Containers in Modular Construction
Shipping container used in modular construction MIAMI, FL, May 24, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: […]
Roadzen to Participate in Fireside Chat at the Maxim Group TMT Conference on June 4, 2024
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN) (“Roadzen” or the “Company”), a global leader in […]
The Children’s Place, Inc. Issues Chairman’s Letter to Shareholders
SECAUCUS, N.J., May 24, 2024 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE), an omni-channel children’s specialty portfolio of brands […]
Rail Vision Reflects on Positive Operational Highlights Since the Start of 2024: Scaling Up Commercialization
Announced first-ever commercial installation of its AI-driven systems in a national railways line Achieved regulatory approval and certificate for railway […]
Monopar Announces CFO Succession
WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing […]
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today […]
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T […]
Alkami to Present at William Blair 44th Annual Growth Stock Conference
PLANO, Texas, May 24, 2024 (GLOBE NEWSWIRE) — Alkami Technology, Inc. (Nasdaq: ALKT) (“Alkami”), a leading cloud-based digital banking solutions […]
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on […]
